Literature DB >> 12126877

A 6-hydroxydopamine lesion of the mesostriatal dopamine system decreases the expression of corticotropin releasing hormone and neurotensin mRNAs in the amygdala and bed nucleus of the stria terminalis.

Heidi E W Day1, Nicole M Vittoz, Matthew M Oates, Aldo Badiani, Stanley J Watson, Terry E Robinson, Huda Akil.   

Abstract

The mesostriatal dopamine (DA) system is known to play a vital role in extrapyramidal motor responses, and animals with a unilateral 6-hydroxydopamine (6-OHDA) lesion of this system have proved useful in studying the behavioral and neurobiological effects of DA depletion. Less is known about the role of this system in modulating emotional responses, although a number of lines of evidence suggest that dopamine influences emotional behavior. During the course of a study involving rats that had a unilateral 6-OHDA lesion, we discovered a hemispheric asymmetry in the levels of corticotropin releasing hormone (CRH) mRNA in the central nucleus of the amygdala (CEA). The present study was performed in order to determine (1) if the lesion resulted in a decrease in CRH mRNA, and/or if there was upregulation on the intact side, (2) if a similar imbalance in CRH mRNA was observed in other brain regions and (3) if levels of other neuropeptide mRNAs were affected by the lesion. Adult male Sprague-Dawley rats were left unoperated or were pretreated with desipramine and then injected unilaterally with 6-OHDA into the medial forebrain bundle to lesion the ascending mesostriatal DA neurons. Animals were killed 15-31 days following surgery and brain sections processed for CRH, neurotensin and enkephalin mRNAs by in situ hybridization. Levels of CRH and neurotensin mRNAs were decreased on the lesioned side in the CEA and oval nucleus of the BST (BSTov) relative to the intact side and to unoperated controls. Levels of enkephalin mRNA in these regions were not affected by the lesion. These effects appeared specific, because the lesion did not alter CRH mRNA expression in the ventral BST, paraventricular nucleus of the hypothalamus or cortex or neurotensin mRNA expression in the CA1 region of the hippocampus. In contrast, and consistent with previous reports, levels of neurotensin and enkephalin mRNAs were upregulated on the lesioned side of the striatum. This study provides evidence that the mesostriatal DA system regulates CRH and neurotensin mRNA in the BSTov and CEA, suggesting that dopamine may be an important modulator of CRH and neurotensin function within these nuclei. Although the precise mechanisms are not clear, and the involvement of noradrenergic systems cannot be precluded, data are consistent with the idea that dopamine, released in response to a stressful experience for example, interacts with CRH and neurotensin in the extended amygdala to affect emotional responsiveness.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12126877     DOI: 10.1016/s0006-8993(02)02747-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  13 in total

1.  D1 dopamine receptor-mediated LTP at GABA synapses encodes motivation to self-administer cocaine in rats.

Authors:  Michal Krawczyk; Xenos Mason; Julian DeBacker; Robyn Sharma; Catherine P Normandeau; Emily R Hawken; Cynthia Di Prospero; Cindy Chiang; Audrey Martinez; Andrea A Jones; Évelyne Doudnikoff; Stephanie Caille; Erwan Bézard; François Georges; Éric C Dumont
Journal:  J Neurosci       Date:  2013-07-17       Impact factor: 6.167

Review 2.  Stress Modulation of Opposing Circuits in the Bed Nucleus of the Stria Terminalis.

Authors:  Sarah E Daniel; Donald G Rainnie
Journal:  Neuropsychopharmacology       Date:  2015-06-22       Impact factor: 7.853

Review 3.  The role of biogenic amine signaling in the bed nucleus of the stria terminals in alcohol abuse.

Authors:  Thomas Louis Kash
Journal:  Alcohol       Date:  2012-03-25       Impact factor: 2.405

4.  Activation of central neurotensin receptors reinstates cocaine seeking in the rat: modulation by a D1/D5, but not D2/D3, receptor antagonist.

Authors:  Vanessa Lopak; Suzanne Erb
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

5.  Anhedonia Following Early-Life Adversity Involves Aberrant Interaction of Reward and Anxiety Circuits and Is Reversed by Partial Silencing of Amygdala Corticotropin-Releasing Hormone Gene.

Authors:  Jessica L Bolton; Jenny Molet; Limor Regev; Yuncai Chen; Neggy Rismanchi; Elizabeth Haddad; Derek Z Yang; Andre Obenaus; Tallie Z Baram
Journal:  Biol Psychiatry       Date:  2017-09-07       Impact factor: 13.382

6.  Effect of low doses of methamphetamine on rat limbic-related neurotensin systems.

Authors:  Mario E Alburges; Amanda J Hoonakker; Nathaniel M Cordova; Christina M Robson; Lisa M McFadden; Amber L Martin; Glen R Hanson
Journal:  Synapse       Date:  2015-06-11       Impact factor: 2.562

7.  Interrelations between monoaminergic afferents and corticotropin-releasing factor-immunoreactive neurons in the rat central amygdaloid nucleus: ultrastructural evidence for dopaminergic control of amygdaloid stress systems.

Authors:  Marina Eliava; Deniz Yilmazer-Hanke; Esther Asan
Journal:  Histochem Cell Biol       Date:  2003-08-09       Impact factor: 4.304

8.  Transgenic mice expressing green fluorescent protein under the control of the corticotropin-releasing hormone promoter.

Authors:  Tamar Alon; Ligang Zhou; Cristian A Pérez; Alastair S Garfield; Jeffrey M Friedman; Lora K Heisler
Journal:  Endocrinology       Date:  2009-10-23       Impact factor: 4.736

9.  Mesolimbic neuropeptide W coordinates stress responses under novel environments.

Authors:  Toshiyuki Motoike; Jeffrey M Long; Hirokazu Tanaka; Christopher M Sinton; Amber Skach; S Clay Williams; Robert E Hammer; Takeshi Sakurai; Masashi Yanagisawa
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-02       Impact factor: 11.205

10.  Conditioned fear inhibits c-fos mRNA expression in the central extended amygdala.

Authors:  Heidi E W Day; Elisa M Kryskow; Tara J Nyhuis; Lauren Herlihy; Serge Campeau
Journal:  Brain Res       Date:  2008-07-02       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.